Home a
 

Keywords :   


Tag: a

Rules - Suspension of Benefits (Exhibit A)

2014-02-21 01:06:01| PortlandOnline

PDF Document, 69kbCategory: Proposed Rule Changes

Tags: a rules benefits exhibit

 

Rules - IME (Exhibit A)

2014-02-21 01:01:22| PortlandOnline

PDF Document, 78kbCategory: Proposed Rule Changes

Tags: a rules exhibit ime

 
 

Rules - Application for Benefits (Exhibit A)

2014-02-21 01:00:50| PortlandOnline

PDF Document, 119kbCategory: Proposed Rule Changes

Tags: a application rules benefits

 

PoL DC/DC Converters come in high-efficiency 12 and 20 A models.

2014-02-10 14:32:08| Industrial Newsroom - All News for Today

Respectively delivering up to 12 and 20 A, 20.32 x 11.43 x 8.55 mm OKL2-T/12 and 33.02 x 13.46 x 8.75 mm OKL2-T/20 offer 93%–95% typ conversion efficiency and come in inspectable Land Grid Array (iLGA) package that facilitates probing of all signal pads and visual inspection. Both non-isolated models have 2 variants that accommodate nominal 5 Vdc (2.4–5.5 Vdc) or 12 Vdc (4.5–14 Vdc) input range; 5 and 12 V models provide programmable output voltages from 0.6–3.63 Vdc and 0.69–5.5 Vdc. This story is related to the following:DC To DC Converters

Tags: a models pol converters

 

Alnylam Initiates Phase 1 Clinical Trial with ALN-AT3, a...

2014-01-23 08:48:30| Biotech - Topix.net

Alnylam Pharmaceuticals , Inc. , a leading RNAi therapeutics company, announced today that it has initiated a Phase 1 study with ALN - AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin for the treatment of hemophilia and rare bleeding disorders .

Tags: a trial phase clinical

 

Sites : [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] next »